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THE EFFECT OF AGING ON THE INNATE IMMUNE RESPONSE 
 OF VASCULAR SMOOTH MUSCLE 
 
Christopher Winterbottom, Bethany Tesar, Ellegant Pearson, Sofya Rodov, and Daniel 
Goldstein.  Section of Cardiology, Department of Internal Medicine, Yale University, 
New Haven Connecticut 
 
As our understanding of atherosclerosis has become more sophisticated, a picture of the 
disease has emerged which emphasizes the role of inflammation in the pathogenesis of 
the disease, including signaling cascades mediated by toll-like receptors (TLRs).  Data 
has also emerged suggesting that the process of aging plays an important role in 
atherogenesis, through pathways at least partially mediated by changes in the function of 
vascular smooth muscle cells.  The purpose of this study was to elucidate the role that 
aging might play in the TLR-dependent innate immune response of vascular smooth 
muscle.  Ex vivo cell and tissue culture models were used, with cytokine and chemokine 
production in response to stimulation with TLR agonists measured by ELISA assays.  
Our study demonstrated differences between aged and young cells and tissue specimens 
in the production of the pro-inflammatory cytokines interleukin 6 (IL-6) and monocyte 
chemoattractant protein 1 (MCP-1), with greater production of IL-6 and less production 
of MCP-1 seen in the aged specimens than in the young specimens.  We discuss these 





Heart disease is the leading cause of death for both men and women in the United 
States, accounting for nearly 30% of all US deaths in 2002 [1]. Coronary heart disease is 
the most common type of heart disease, with a lifetime risk of 49% for men and 32% for 
women at age 40.  Even among adults who have reached age 70 without CHD, the 
lifetime risk is 35% for men and 24% for women [2]. Although the incidence and 
mortality of CHD and cardiovascular disease overall have decreased over the last 20 
years with the advent of new therapies and lifestyle modifications including smoking 
reduction, the changing demographics of the American population suggest that CHD will 
remain a significant threat to public health for years to come.   
Among the most important demographic shifts in the American population with 
regards to coronary heart disease is the population’s advancing age.  CDC estimates 
indicate that the proportion of Americans aged 65 or older is expected to increase from 
12.4% in 2000 to 19.6% in 2030.  The absolute number of Americans aged 65 or older is 
expected to rise even more dramatically, doubling from 35 million in 2000 to 71 million 
in 2030 [3].  The number of Americans over age 80 is expected to double during this time 
period as well, from 9.3 million in 2000 to 19.5 million in 2030.  These demographic 
shifts in the American population are significant, as over 83% of deaths due to coronary 
heart disease occur in patients aged 65 or older, accounting for over 40% of deaths in that 
age group. Indeed, age per se is thought to be the most important risk factor for the 
development of coronary heart disease [4]. 
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Pathogenesis of Atherosclerosis: 
 
To understand why the risk of coronary heart disease increases so dramatically 
with age, it is important to understand the pathogenesis of the disease.  The primary event 
leading to the development of coronary artery disease, as well as other types of vascular 
diseases including cerebral and peripheral artery diseases, is atherosclerosis.  
Atherosclerosis primarily affects the elastic and large muscular arteries of the body 
(including the aorta, carotid, and coronary arteries), and becomes symptomatic when the 
diameter of these large arteries becomes sufficiently narrowed to compromise the blood 
flow to end organs such as the brain, kidneys, or the heart.  In the heart, the inability of 
the coronary blood supply to match the heart’s demand due to arterial narrowing leads to 
angina, and the complete cessation of blood flow, usually caused by rupture of the 
atherosclerotic plaque, leads to myocardial infarction.   
 As the understanding of atherosclerosis has evolved, the notion of the disease as a 
simple problem of plumbing has become outdated, and in its place has emerged a picture 
of a complex inflammatory disease characterized by intense immunological activity.  The 
primary event in the development of atherosclerosis is injury to the vascular endothelium, 
a single cell layer that serves as a barrier between the circulation and the internal 
components of the vessel wall. The culprits of endothelial injury are wide-ranging, and 
include hyperlipidemia, toxins including those present in tobacco smoke, bacteria and 
viruses, immune reactions, and hemodynamic disturbances including those arising from 
hypertension. 
 3
 Injury to the vascular endothelium leads to impairment of endothelial function, 
and alterations of the endothelium’s normal hemostatic properties.  As a result, injured 
endothelium has increased adhesive properties with respect to leukocytes and platelets, as 
well as increased permeability.  This increased adhesiveness is mediated by an increase in 
the endothelial expression of adhesion molecules, including vascular cell adhesion 
molecule-1 and P-selectin [5].  These cell-surface molecules interact with circulating 
monocytes and lymphocytes, slowing their progress through the bloodstream, and 
allowing them to respond to chemotactic stimuli in the nearby environment.  One such 
chemoattractant factor produced by cells in the vessel wall in response to modified 
lipoproteins is monocyte chemoattractant protein 1 (MCP-1).  MCP-1 and other 
chemoattractant factors direct the migration of monocytes through the endothelial layer 
and into the vascular wall.  Other functional changes induced by injury to the vascular 
endothelium include the formation of vasoactive molecules, as well as assorted cytokines 
and growth factors [5].  
 Macrophage colony stimulating factor, which is overexpressed in inflamed 
intima, directs the maturation of monocytes into macrophages once they reach the intima 
[6].  These macrophages then augment their expression of scavenger receptors and engulf 
modified lipoproteins through receptor-mediated endocytosis.  The end result of this 
process is the lipid-laden foam cell, the characteristic inhabitant of the early 
atherosclerotic lesion.  In addition to their phagocytic role, these macrophages also 
secrete numerous growth factors and cytokines, including TNF-α and IL-1β, which 
amplify the ongoing inflammatory response [5].   
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 The adaptive immune system plays a crucial role in the development of 
atherosclerosis as well, primarily through the work of CD4+ T cells.  These T cells, 
which recognize fragments of antigens presented by cells expressing major 
histocompatibility complex class II molecules, are also known as helper T cells.  The 
cytokine milieu in the atherosclerotic lesion, including IL-12 and IL-18 produced by 
macrophages and smooth muscle cells in plaques, promotes the induction of a Th-1 
response among these T cells, and the differentiation of these T cells into Th-1 effector 
cells [7].  These Th-1 cells amplify the localized immune response through the 
production of proinflammatory cytokines including IFN-γ and TNF, as well as the CD-40 
ligand.  These Th-1 cytokines promote the development of atherosclerosis in a variety of 
ways.  IFN-γ activates macrophages, leading to increased production of nitric oxide, pro-
inflammatory cytokines, vasoactive and pro-thrombotic mediators.  IFN-γ also inhibits 
the proliferation of endothelial cells and the differentiation of vascular smooth muscle 
cells, and SMC collagen production [8], [9].  It is thought that decreasing the cellular and 
collagenous content of the cap’s fibrous plaque decreases the plaque’s stability, leading 
to greater risk of thrombosis [10].   
 Tumor necrosis factor (TNF) contributes to inflammation by activating the NF-κB 
signaling pathway, leading to the generation of reactive oxygen species, proteolytic 
enzymes, and tissue factor by endothelial cells[11].  In addition to its pro-inflammatory 
effects, TNF has significant metabolic effects, including the suppression of lipoprotein 
lipase, which results in the accumulation of lipoproteins rich in triglycerides in the blood.  
Elevations in TNF levels, and the accumulation of such lipoproteins have been associated 
with the development of heart disease in clinical studies.   
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 The first stage of atherosclerosis, the so-called fatty streak, is a purely 
inflammatory lesion, composed primarily of foam cells, with some T-lymphocytes.  
These lesions are not raised significantly from the vessel wall, and thus do not cause any 
disturbances in arterial blood flow.  They have been seen in children as young as 1 year 
old, and occur in all children by the time they reach age 10 [12].  While the fatty streak is 
thought to be the precursor of the atherosclerotic plaque, their universal prevalence in the 
arteries of all humans, and their frequent location in arteries and populations not typically 
prone to atherosclerosis indicates that not all fatty streaks are destined to become 
atheromas, and that additional events are necessary for the development of a more 
complex atherosclerotic lesion. 
 The definitive event that differentiates a fatty streak from a more advanced 
atherosclerotic lesion is the deposition of fibrous tissue in the plaque.  The majority of the 
extracellular matrix that is laid down comes from smooth muscle cells (SMCs).  During 
this phase of plaque formation, SMCs migrate from the tunica media into the intima, 
under the influence of platelet-derived growth factor secreted by endothelial cells and 
activated macrophages [13].  This migration is facilitated by the secretion of MMP-9 and 
other proteases secreted by the SMCs, which degrade the existing extracellular matrix.  
Once the SMCs have arrived in the intimal layer, under the influence of various growth 
factors including transforming growth factor β and platelet-derived growth factor, they 
begin to proliferate and secrete extracellular matrix proteins.  It is this migration and 
secretion of ECM proteins by SMCs that causes the transformation of the purely 
inflammatory lesion of the fatty streak into a fibrotic and ultimately calcified plaque that 
can have functional consequences for downstream arterial flow [5].   
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Histologically, this primary lesion of atherosclerotic disease, the atheroma, is a 
raised focal lesion within the vessel intima, with a soft lipid core primarily composed of 
cholesterol and associated esters, and a firm fibrous cap.  There are three principal 
components of these plaques: cells, including smooth muscle cells, macrophages, and 
other leukocytes, extracellular matrix, and intracellular and extracellular lipid.  The 
superficial cap of the plaque is typically composed of SMCs and collagen.  Beneath and 
around the cap, in a cellular area known as the “shoulder” of the plaque, can be found a 
particularly high concentration of macrophages and T lymphocytes, as well as SMCs 
[14].  This is the area from which much of the plaque’s growth occurs.  Other cell types 
found within plaques include dendritic cells, mast cells, a few B lymphocytes, and natural 
killer T cells [10].  Deep to this cellular area is a disorganized mass of lipid and debris 
known as the necrotic core of the plaque.  The cellular component of the necrotic core of 
the atherosclerotic lesion is primarily foam cells.  As previously mentioned, these large 
cells, laden with cholesterol and other lipids, are primarily derived from migratory 
macrophages, although smooth muscle cells can also engulf lipid to become foam cells.  
The atherosclerotic plaque is a dynamic lesion, evolving with time as cell death and 
degeneration, as well as calcification and the synthesis and remodeling of extracellular 
matrix lead to enlargement of the plaque, with consequent narrowing of the arterial lumen 
and disruption of blood flow to downstream organs. 
On top of this chronic process of plaque evolution and enlargement, acute focal 
plaque rupture, ulceration, or erosion can lead to the exposure of highly thrombogenic 
elements of the plaque to the circulation, and the superimposition of intravascular 
thrombosis on the luminal narrowing caused by the extravascular plaque.  It is these 
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acute-on-chronic disturbances, leading to severe obstruction or complete occlusion of the 
vasculature, that leads to the most feared complication of atherosclerosis, myocardial 
infarction (MI).  Interestingly, in many cases of MI, the lesion whose rupture was 
ultimately responsible for the thrombotic vascular occlusion causing the MI did not 
produce a critical arterial narrowing prior to rupture [15].  In other words, the lesions 
responsible for chronic symptomatic coronary artery disease (i.e. angina) are not 
necessarily the same lesions which ultimately lead to those patients’ deaths.  Recent 
studies suggest that it is the activation of inflammatory pathways, rather than simply the 
degree of stenosis, that places plaques at risk for rupture and leads to thrombosis and 
resultant ischemia and infarction [16].   
As mentioned earlier, one aspect of the inflammatory response that predisposes 
plaques to rupture is the production of IFN-γ by resident T cells, which denudes the 
fibrous cap of its cellular and collagen components, decreasing its stability.  Other T cell 
controlled changes that decrease plaque stability include release of IL-1 and CD40 
ligand, which induce macrophages to release interstitial collagenases, such as MMP-1, 
MMP-8, and MMP-9.  Plaque analysis has revealed that MMP-9 is catalytically active, 
and that overexpression of MMP-9 may promote the production of tissue factor and lead 
to tissue factor-mediated activation of the coagulation cascade [17].   
The rupture of an unstable plaque leading to acute coronary syndrome is typically 
precipitated by the physical disruption of the plaque’s fibrous cap, either due to frank cap 
rupture or erosion of the endothelium.  Contact between the blood and the thrombogenic 
substances in the lipid core and elsewhere in the plaque initiates the formation of 
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thrombus.  Once formed, a thrombotic occlusion can have sudden and catastrophic effects 
on blood flow to tissue downstream of the occlusion, and ultimately lead to death.  
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Role of Toll-Like Receptors: 
 
 As the picture of atherosclerosis as a chronic inflammatory disease has evolved 
over the past few decades, so too has the understanding of the immune system as a whole.  
One of the most dramatic areas of growth in our understanding of this complex system is 
the discovery and study of the Toll-like receptor (TLR).  The Toll gene was first 
discovered by the German scientist Nusslein-Volhard in Drosophila in the mid-1980s, 
and the vertebrate homolog was discovered only in 1997.  Toll-like receptors are a family 
of pattern recognition receptors that are now known to play a key role in both the innate 
and adaptive immune systems.  To date, 11 distinct mammalian TLRs have been 
identified, each of which interacts with a distinct array of conserved microbial molecular 
sequences.  
TLRs are type 1 membrane-spanning receptors, with leucine-rich repeat motifs 
and signaling motifs similar to those found in the IL-1 and IL-18 receptors.  Most TLRs 
are cell-surface receptors. The exceptions are TLR 3, 7, 8, & 9, which are involved in 
viral recognition, and are found largely in the endosomal compartment [18].  All four are 
involved in viral recognition [19].  In binding to their ligands, TLRs form either homo or 
heterodimers, with each dimer having a different ligand specificity.  TLRs 1, 2, 4, 5 & 6 
are specialized to recognize unique bacterial products that are not made in the host, 
including the gram-negative bacterial outer membrane component lipopolysaccharide 
(TLR-4), flagellin (TLR-5), lipoteichoic acid and peptidoglycan (TLR-2), and 
lipoproteins.  In addition to the unique microbial patterns that they recognize, TLRs have 
been shown to recognize endogenous molecules, including fibrinogen, heat shock 
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proteins, oxidized lipids, fibronectin, and surfactant protein A [20].  In addition to these 
endogenous molecules, TLRs have been shown to recognize degradation products of 
endogenous macromolecules, such as heparin sulfate and hyaluronan.  This intriguing 
discovery indicates that, via TLRs, the extracellular matrix can stimulate the innate 
immune response when it has been altered as a result of tissue destruction [18].  It is 
thought that surveillance for such degradation products, released by injured or infected 
tissues, may be an integral part of the TLRs role in “keeping watch” for tissue damage 
[21].   
Once TLRs have recognized and bound to their ligands via molecular pattern 
recognition, they tend to cluster, recruit accessory proteins and set in motion the complex 
NF-κB signaling cascade that ultimately leads to the translocation of NF-κB into the 
nucleus, and activation of gene transcription.  The genes transcribed as a result of NF-κB 
signaling typically code for pro-inflammatory cytokines, including IL-1, IL-6, and IL-8.  
TLR signaling also induces the production of antimicrobial molecules, such as nitric 
oxide.  This response enables macrophages to engulf and eliminate invading 
microorganisms [18].  The activation of TLRs expressed on dendritic cells stimulates 
their maturation, which allows them to stimulate the expansion and differentiation of T 
cells, providing a link between TLR function and activation of the adaptive immune 
system.  TLR signaling has also been shown to induce the production of chemokines, 
polyreactive antibodies, and costimulatory molecules such as CD80 (B7-1) and CD86 
(B7-2) that can lead to sustained activation of the adaptive immune system [19, 22].  
Toll-like receptors are also involved in the activation of complement, coagulation, 
phagocytosis, and apoptosis. 
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Over the past decade, a role for Toll-like receptors as surveillance receptors with 
substantial influence over the immune response has emerged.  As this picture has 
evolved, new research has gotten underway to elucidate what role these receptors might 
play in the development of the chronic inflammatory disease of atherosclerosis.  One 
possible link between TLR signaling and atherosclerosis has been postulated to occur 
through chronic infection.  For twenty years, epidemiologic data has been available 
linking seropositivity for Chlamydia TWAR and acute MI and chronic coronary heart 
disease [23].  Furthermore, studies have shown that many human atherosclerotic plaques 
show signs of infection with Chlamydia pneumoniae [24].   
This discovery raised the tantalizing possibility that Chlamydia species acted as 
an infectious vector capable of stimulating atherogenesis.  Such a link would provide a 
clear mechanistic role for Toll-like receptor signaling in the pathogenesis of 
atherosclerosis, and would also provide a clear target for drug therapy aimed at 
eradicating Chlamydia infection. Limited data from animal studies have indicated that 
Chlamydia infection can accelerate atherosclerosis and treatment with azithromycin can 
prevent this acceleration [25].  Unfortunately, a large randomized prospective trial of 
weekly azithromycin treatment for a period of 1 year in patients with documented stable 
coronary artery disease failed to demonstrate any mortality benefit for patients taking 
azithromycin when compared to a placebo [26].  Other studies looking at atherosclerotic 
lesions in the carotids and peripheral arteries have similarly failed to demonstrate a 
benefit from antibiotic treatment.  However, these studies were limited by the advanced 
age of the participants and the presumably long lag time between inoculation and 
antibiotic treatment. While firm evidence linking infection with the atherosclerotic 
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process has not been produced to date, the results of these studies are far from conclusive, 
and do not necessarily exclude the possibility of a role for infectious agents in the 
pathogenesis of atherosclerosis.   
More intriguing evidence for the role of Toll-like receptor signaling in the 
pathogenesis of atherosclerotic disease comes from analysis of genetic polymorphisms 
coding for TLRs.  Of all the polymorphisms thus far identified, two mutations in TLR-4 
have been studied the most extensively – Asp299Gly and Thr399Ile.  These 
polymorphisms were initially thought to be related to hyporesponsiveness to 
lipopolysaccharide (LPS), the gram-negative bacterial outer membrane component 
recognized by TLR-4.  The initial study examined a physiologic response (decline in 
FEV1) in response to LPS inhalation [27].  Another study demonstrated that Asp299Gly 
was statistically overrepresented among adult patients admitted to the ICU with septic 
shock, suggesting that the polymorphism may predispose patients to the development of 
septic shock [28].  However, a subsequent study examining the in vitro response of donor 
monocytes to LPS demonstrated no difference between either polymorphism and wild-
type monocytes in terms of response to LPS, and the significance of these polymorphisms 
in terms of host defense is not yet clear [29]. 
Initial studies of the effect of these polymorphisms on the risk of developing 
atherosclerotic disease seemed to indicate that these alleles were protective.  A study on 
carotid intima-media thickness as measured by Doppler ultrasound indicated that patients 
carrying these alleles had less intima-media thickening, and a lower risk of developing 
carotid atherosclerosis [30].  Several larger studies, however, were unable to reproduce 
this result [31].  Research into the effects of these polymorphisms on the risk of MI has 
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so far been inconclusive as well.  While most studies have reported a reduced risk of MI 
in patients carrying one of the polymorphisms, the largest such study, which included 
nearly 5,000 individuals, found no association between cardiac risk and either of the 
polymorphisms [18, 32].  In a meta-analysis of 7 of these studies, the pooled odds ration 
for MI was 0.9 (95% CI 0.68-1.19), suggesting some protective role for the alleles against 
myocardial infarction, but lacking the power to demonstrate statistical significance [18].  
Larger studies will be needed in the future to determine conclusively whether the TLR-4 
polymorphisms convey protection against the development of atherosclerotic disease. 
The idea that TLRs are involved in the pathogenesis of atherosclerotic disease is 
further supported by correlations seen in recent clinical studies.  One such study, which 
examined the peripheral circulating monocytes in patients immediately post-MI, found 
that these patients exhibited elevated levels of pro-inflammatory cytokines, most notably 
TNF-α and IL-6, which positively correlated with elevated expression of TLR-4 on the 
patients’ monocytes [33].  Other studies have corroborated this result, and have suggested 
that upregulation of TLR-4 sensitizes monocytes, while downregulation of TLR-4 
decreases their ability to mount a pro-inflammatory response [34].  The results of these 
studies have generated ongoing interest and further research aimed at the elucidation of a 
possible role for TLR-4 signaling in the inflammatory state of acute MI. 
Experimental data on inflammatory signaling pathways in atheromas have 
supported the proposed role for TLR signaling in the development of atherosclerosis.  
Expression levels of TLR-1, -2, and -4 have been shown to be markedly elevated (by 
semi-quantitative PCR) among the resident cells of human atherosclerotic plaques [35], 
particularly among macrophages and endothelial cells.  Furthermore, TLR-4 expression 
 14
can be upregulated by the presence of proatherogenic oxidized LDL, while TLR-2 
expression can be downregulated by laminar, non-turbulent blood flow [18]. 
Studies using murine knockout models of TLR genes have provided convincing 
further evidence of a role for these receptors in the development of atherosclerosis.  
Because normal mice have more rapid hepatic LDL clearance than do humans, they do 
not develop atherosclerosis unless fed with high cholesterol diets for long periods of time 
[36].  Therefore, in order to develop a useful mouse model of atherosclerosis, it was 
necessary to develop a strain of mice deficient in a gene product involved in cholesterol 
metabolism – apolipoprotein E (ApoE).  ApoE functions as a ligand for receptors that 
clear very low-density lipoprotein (VLDL) and chylomicron remnants.  Mice deficient in 
the gene coding for ApoE have exceedingly high total cholesterol levels, particularly 
when fed Western diets, and develop atherosclerosis at an accelerated pace that makes 
them a workable experimental model for the pathogenesis of the disease [37].   
A cross between Tlr4 knockout mice and ApoE knockout mice yielded double 
homozygous progeny with a reduced burden of atherosclerosis when compared to the 
ApoE -/- controls, despite similar lipid profiles [38].  Studies of mice deficient in MyD88, 
an adaptor protein critical for TLR signal processing, found similar reductions in 
atherosclerotic burden.  When compared to ApoE knockout mice, MyD88/ApoE double 
knockout mice had 60% fewer atherosclerotic lesions [38].   
 In addition to the strong evidence linking TLR-4 signaling to atherosclerotic 
disease, evidence also exists of a role for TLR-2 signaling in the development of 
atherosclerosis.  The double homozygous progeny of Tlr2 knockout mice with LDL 
receptor knockout mice (Ldlr) showed a modest reduction in atherosclerosis when 
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compared to controls.  On the other hand, administration of a TLR-2 agonist led to 
dramatically increased atherosclerosis in Ldlr knockout mice when compared with 
Ldlr/Tlr2 double knockouts [39].    While the body of evidence linking TLR-2 signaling 
to atherosclerosis is not as robust as that linking TLR-4, there does seem to be a link, and 
further studies to strengthen this link are ongoing.   
 As evidence for the role of TLR signaling in the development of atherosclerosis 
has continued to mount, there has remained some confusion as to the role of TLR 
signaling in vascular smooth muscle cells.  As mentioned previously, vascular smooth 
muscle cells are known to play a crucial role in the development of atherosclerosis 
through their migration and production of ECM, as well as their ability to act as 
phagocytic cells.  Until recently, it was thought that VSMCs did not express TLRs [10].  
However, recent data suggests that vascular smooth muscle cells do in fact express both 
Toll-like receptors, and that activation of TLR-4 receptors on VSMCs can induce the 
production of pro-inflammatory cytokines that may play a role in the immune response 
that leads to the development of atherosclerosis.   
In a paper published in the American Journal of Physiology (Heart and 
Circulatory Physiology) in 2005, Yang et al demonstrated that the mRNA coding for 
TLR-4, as well as the mRNA for several key coreceptor proteins, could be isolated from 
both murine and human VSMCs [40].  Furthermore, they showed that the pro-
inflammatory cytokines MCP-1 and IL-6 were expressed at high levels by VSMCs 
stimulated with LPS.  To strengthen the evidence that this production was due to TLR-4 
signaling, they infected mice with a recombinant adenovirus engineered with a dominant 
negative form of the murine TLR-4 gene.  When compared with VSMCs from mice that 
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had been infected with a control adenovirus that did not affect the TLR-4 gene, VSMCs 
from these mice showed markedly reduced production of the pro-inflammatory cytokine 
MCP-1 in response to LPS stimulation (mice with intact TLR-4 signaling showed a 33-
fold increase in MCP-1 production upon LPS stimulation, while mice with TLR-4 
deficiency showed no elevation from baseline signaling [40].  The findings of this study, 
within the context of the existing evidence linking inflammation and TLR-4 signaling to 
atherosclerosis, suggest a role for TLR-4 signaling within vascular smooth muscle cells 
as part of the inflammatory response leading to the development of atherosclerosis. 
 Monocyte chemoattractant protein 1 (MCP-1) is a chemokine thought to play an 
important role in the recruitment of monocytes into the subendothelium of damaged 
arteries.  Extensive evidence exists linking this chemokine to this process.  All of the 
cellular components of the arterial wall, including endothelial cells, smooth muscle cells, 
and fibroblasts, have been shown to secrete MCP-1 in response to known atherogenic 
stimuli, including modified low density lipoprotein and fluid shear stress [41, 42].  In 
addition, MCP-1 expression has been shown to occur in the arterial wall of rabbits and 
non-human primates in vivo in response to hypercholesterolemia [43, 44].  Furthermore, 
two murine knockout studies crossing MCP-1 and CCR-2 (the MCP-1 receptor) deficient 
mice demonstrated markedly decreased lipid plaque formation when compared with 
controls.  This data strongly supports a key role for the chemokine MCP-1 in the 
development of atherosclerosis.   
 IL-6 is an important cytokine inflammatory mediator that might play a role in the 
pathogenesis of acute coronary syndromes.  Like CRP, IL-6 has been found to become 
markedly elevated during acute coronary syndromes, and the degree of elevation is 
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associated with prognosis.  A study showed it to be undetectable in the blood of 
controlled subjects, but elevated in 21% of patients with stable angina, 61% of patients 
with unstable angina, and 83% of patients with unstable angina requiring a prolonged 
hospitalization without troponin or CK-MB leaks [45].  Furthermore, IL-6 elevation has 
been shown to predict the risk of future cardiac events, with a 44% relative risk of future 
MI for each quartile increase of IL-6 concentration from baseline [46]. 
 IL-6 has also been shown to stimulate the growth of vascular smooth muscle cells 
in vitro [47], and IL-6 gene transcripts have been demonstrated in human atherosclerotic 
lesions [48], suggesting a possible role for IL-6 in the pathogenesis of atherosclerosis.  
However, vascular injury studies using IL-6 knockout mice have thus far failed to 
demonstrate significant differences between these mice and those in control groups, [49, 
50]. This failure raises the question of whether IL-6 is in fact a direct mediator of 
atherosclerosis, or more simply a marker of the inflammatory response.   Research into 
the role that IL-6 might play in the pathogenesis of atherosclerosis is ongoing.  Given the 
evidence linking TLR-4 signaling to atherosclerosis, the direct activation of production of 
IL-6 by TLR-4 stimulation, and the role of IL-6 in promotion of the inflammatory 
response, a role for IL-6 may ultimately be demonstrated in the vascular biology of 
atherosclerosis, although its role is unclear at this point. 
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Effect of Aging: 
 
 As previously discussed, atherosclerotic disease, the leading cause of death in the 
United States, is largely a disease of the elderly.  Age has long been known to be the 
single most important risk factor for the development of cardiovascular disease.  A 
traditional explanation for the increased disease burden among older patients is that 
atherosclerotic lesions develop slowly over time, as the result of the accumulation of 
large numbers of small vascular insults, leading to the progressive development of more, 
larger, and less stable atheromas as patients age, which simply increases the risk of 
developing clinically significant lesions.  However, a body of evidence is emerging 
which suggests that the effects of aging cannot be explained simply by the accumulation 
of injuries over time, and that the vascular immune response may undergo some intrinsic 
change with the process of aging that predisposes it to the development of 
atherosclerosis. 
 Much of the evidence for the role of aging in the inflammatory response of the 
vasculature comes from the field of transplant biology.  Although advances in 
immunosuppressive protocols have decreased the rates of acute transplant rejection, 
almost half of all vascularized organ grafts are still lost at a certain point post-transplant.  
The most common cause of chronic transplant rejection is transplant arteriosclerosis [51].  
Research into the cause of this arteriosclerosis has revealed a role for both the age of the 
vessel, and the age of the host, in promoting arteriosclerosis, suggesting that aging is a 
complex process with effects both locally and systemically that promote accelerated 
arteriosclerosis. 
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 Experimental data from rabbits, primates, mice and rats has demonstrated that 
aged animals exhibit a greater degree of neointimal hyperplasia than do their young 
counterparts when subjected to a mechanical endothelial injury [52, 53].  This difference 
is thought to stem from changes in the vascular smooth muscle cells induced by aging 
including increased proliferation due to increased responsiveness to growth factors such 
as platelet-derived growth stemming from increased expression of the PDGF receptor 
[53-55], as well as decreased susceptibility to apoptosis [56], and increased deposition of 
extracellular matrix [57].   
 In addition to these local effects of aging on the vascular response to injury, 
evidence is emerging of systemic effects of aging that increase inflammation and 
atherogenesis as well.  Research in transplant biology has demonstrated that the age of 
the recipient is the most important determining factor in predicting renal allograft 
rejection outcome [58].  An animal model of aortic transplantation, in which aortas from 
aged rats were denuded of endothelium and transplanted into young rats and vice versa, 
demonstrated that the degree of intimal hyperplasia seen in the vascular graft was more a 
function of recipient age than donor age [58].  This is consistent with data that 
demonstrates higher systemic levels of pro-inflammatory cytokines including TNF-α 
associated with aging [59].  As research in this field continues, further evidence of the 
role of aging on local and systemic inflammatory signaling will continue to emerge, 






 In summary, a large body of evidence has emerged in the field of vascular biology 
painting a picture of atherosclerosis as an inflammatory disease.  Toll-like receptor 
signaling, particularly signaling with TLR-4, appears to play a key role in the 
pathogenesis of atherosclerosis, through the production of inflammatory cytokines.  
Vascular smooth muscle cells have been demonstrated to express pro-inflammatory 
cytokines and chemokines, including MCP-1 and IL-6, in response to stimulation with 
the TLR-4 agonist lipopolysaccharide.  Furthermore, the process of aging may accelerate 
atherogenesis through alterations in the activity of vascular smooth muscle cells.  In this 
context, this project sought to explore the role that aging might play in the innate immune 
response of vascular smooth muscle cells in response to TLR stimulation, using ex-vivo 
cell and tissue culture techniques, and measuring the cellular and tissue response to 
stimulation through ELISA-based assays of pro-inflammatory cytokine production. 
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Statement of Purpose/Specific Aims: 
 
 The purpose of this study was to evaluate the effect of aging on the innate 
immune response of vascular smooth muscle, using a murine model and ex vivo cell and 
tissue culture techniques.  This was done using TLR stimulation, with assays measuring 





 Our hypothesis was that aged vessels would exhibit increased production of pro-
inflammatory cytokines when compared to young vessels in response to stimulation with 
Toll-like receptor 4 agonists. 
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Cell cultures were isolated from young and aged mice from a CBA background, 
with 3-4 mice pooled per group.  For the tissue culture experiment, all mice were from a 
CBA background.  Aged mice were 19-20 months old.  The first experiment used 3 aged 
and 3 young mice, with supernatants collected from tissue cultures from each mouse at 1 
time point each (1 aged and 1 young mouse was stimulated for 6 hours, 1 each for 24 
hours, and 1 each for 48 hours).  The second experiment used 3 young and 6 aged mice, 
with supernatants collected from each cultured vessel at 4 separate time points (12, 24, 
48, and 72 hours).  To test the role of T cells we depleted two of the aged mice in this 
experiment with CD4 (clone GK.15) and CD8 (clone 2.43) depleting T cells. 
 
Vascular smooth muscle cell isolation: 
 
 Mice were euthanized with ketamine overdose. A large incision was then made in 
the midline of each mouse, extending from the pelvis to the suprasternal notch, and their 
rib cages were removed, exposing the heart and other internal organs.  The descending 
aortas were then isolated and stripped of fat tissue and adventitia, and placed in a 20ml of 
ice-cold Dulbecco’s Modified Eagle’s Medium (DMEM). 3-4 aortas were pooled for 
each age group.  The 3-4 aortas were then placed in collagenase type II and incubated at 
37 degrees for 15 minutes.  At this point, remaining adventitia was removed, and aortas 
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were transferred to a dish containing collagenase I/elastase, and cut into small pieces with 
a scalpel blade.  Next, these pieces were incubated at 37° Celsius for 60 minutes, with 
forceful pipetting of the mixture containing the pieces done every 15 minutes to ensure 
dispersal of cells.  The digestion was then stopped by the addition of 5ml of mouse aorta 
growth medium (MAGM) which included 20% fetal bovine serum, 1% 
penicillin/streptomycin, 1% mixed non-essential amino acids, and 1% L-glutamine.  Cells 
were then spun at 1500 rpm for 8 minutes at room temperature.  The supernatant was 
then removed, and the cells were spun again in 2 ml of MAGM after resuspension.  Cells 
were then resuspended in 2ml MAGM and plated in a 6 well plate coated with fibronectin 
(Biocoat).   
 





 Once the vascular smooth muscle cells were isolated, they were cultured in flasks 
in MAGM.  Media was changed twice weekly, and cells were allowed to grow until 
convergence, at which point they were trypsinized and regrown in a new flask to prevent 
overgrowth. 
 
This was done by the student. 
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Vascular smooth muscle cell phenotyping – Alpha SMC actin staining: 
 
 Cells from culture flasks were trypsinized and transferred to large plates 
containing glass slides, and cultured to confluence in MAGM  Slides coated with cells 
were then washed in PBS twice, and fixed for three minutes in ice-cold methanol.  Slides 
were then allowed to air dry.  Slides were then incubated for 45 minutes with 10% 
normal goat serum in phosphate buffered saline at room temperature.  Cells were then 
incubated for 90 minutes at 37° Celsius with Sigma mouse anti-SMC actin (IgG2) 1:400 
in PBS/2% Bovine Serum Albumin (BSA).  Cells were then rinsed once and washed with 
PBS 3 times for 5 minutes each.  Cells were then incubated for 45 minutes in the dark 
with Alexa flour 488 goat anti-mouse IgG (1:500 in PBS/2% BSA).  Cells were then 
rinsed once, and washed with PBS 3x for 5 minutes each.  Cells were then placed in 
Hoechst 1:10,000 for 3 minutes.  Next, cells were washed twice with PBS.  Cells were 
then mounted in glycerol/PBS and visualized. 
 
This step was completed by the student under the supervision of lab technician Sofya 
Rodov, although data presented below is from a separate trial in which the student was 





 For the purposes of cell stimulation, cells were trypsinized and counted under 
microscopic visualization in order to ensure equal distribution.  To each well of a 48 well 
plate, 10,000 cells were added, and incubated in 500 μl of 1% FBS in DMEM media for 
24 hours to coordinate their progress through the cell cycle at G0.  Cells were then 
incubated for 6 to 72 hours in 0.25% FBS in DMEM media.  To this media, 0.5 ng/ml of 
LPS was added to cells in the LPS stimulation group, matched with unstimulated 
controls.  Other TLR agonists were added to separate samples with concentrations of 0.5 
ng/ml (peptidoglycan), 2ng/ml (poly I:C), 2ng/ml (flagellin), and 10ng/ml (CpG).  All 
media was removed from each well at the indicated time point, and ELISA assays were 
run per the manufacturer’s protocol to determine the concentration in each cell group. 
 
Some trials of this step were completed by the student, although data presented below is 
from work done prior to student’s arrival. 
 
Tissue culture model: 
 
 For the second phase of the project, an ex-vivo tissue culture model was used, 
comparing vessels obtained from aged and young mice.  Mice were euthanized by 
isofluorane inhalation, followed by cervical dislocation.  A large incision was then made 
in the midline of each mouse, extending from the pelvis to the suprasternal notch, and 
their rib cages were removed, exposing the heart and other internal organs.  Preceding the 
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tissue isolation, a small hole (~ 2mm) was cut in the right atrium of each mouse’s heart.  
Next, each mouse’s left ventricle was pierced with a 22 gauge needle, and injected with 
approximately 10ml of phosphate-buffered sodium, in order to flush out the blood from 
the mice’s left-sided circulation.  The mice’s lungs, esophagus, and inferior vena cavas 
were then removed.  The descending aortas, made clearly visible by this dissection, were 
isolated from both young and aged mice under direct and microscopic visualization, and 
care was taken during this process to remove the adventitia and peri-aortic fat, lymph 
nodes, and connective tissue surrounding the vessels.  The vessels were then transected at 
their approximate mid-point, and each vessel was washed in 1ml of phosphate-buffered 
saline solution.  Following the completion of these dissections, the vessels pieces were 
transferred into 96-well plates containing 200 μL of M199 media containing 20% fetal 
bovine serum, as well as 1% penicillin/streptomycin, and 1% l-glutamine.  These vessels 
were then incubated at 37° Celsius for 4 hours.  Following incubation, 50 μl of media 
was added to each well for a total of 250 μl per well.  For one vessel piece per mouse, 
0.5ug/ml of LPS was added to the media.  Media was then removed from the tissue as 
follows:  For the first group of mice, all media was removed at one time point for each 
mouse – at 6 hours, 24 hours, and 48 hours, respectively.  For the second group of mice, 
50 μl of media was taken off from each vessel piece at 12 hours, 24 hours, 48 hours, and 
72 hours. ELISA assays were run per the manufacturer’s protocol to determine the 
concentration in each supernatant. 
 




Cultured cells display the phenotype of vascular smooth muscle cells: 
 
 In order to demonstrate that the cytokines measured from our stimulation 
experiments were indeed produced by vascular smooth muscle cells in response to TLR 
stimulation, we first needed to demonstrate that we had successfully isolated and cultured 
vascular smooth muscle cells.  To that end, cultured cells isolated from both young and 
aged mice were stained via immunofluorescence for smooth muscle cell specific actin.  
Cells from both young and aged mice from both cell lines demonstrated the presence of 
this cytoskeletal protein in abundance, indicating that all, or least the vast majority, of 
cells used for the stimulation experiment, were indeed vascular smooth muscle cells.   
  




Figure 2: Immunofluorescence staining of cells derived from young CBA mice 
 
Cell culture experiment: IL-6 production is elevated and MCP-1 production 
decreased in aged cells when compared to young cells in an ex vivo cell culture 
model 
 
 We stimulated the cultured cells with various TLR agonists, including LPS (TLR-
4), peptidoglycan (TLR-2), Poly I:C (TLR-3), CpG (TLR-9) and flagellin (TLR-5), and 
measured their expression of the pro-inflammatory cytokine IL-6 and the chemokine 
MCP-1.  The results of these experiments are shown in figures 3-16 below.  The 
production of both MCP-1 and IL-6 was markedly elevated following LPS stimulation 
when compared to the other TLR agonists, a finding consistent with the documented role 
of TLR-4 signaling in the development of atherosclerosis, and the documented presence 
and activity of the TLR-4 receptor on vascular smooth muscle cells.  Stimulation with 
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flagellin (TLR-5) and peptidoglycan (TLR-2) led to marked elevations of cytokine 
production above baseline as well, while the other TLR agonists did not markedly elevate 
the production of these pro-inflammatory cytokines (figures 8-9, 15-16).   
During this first series of experiments, IL-6 production was markedly elevated in 
aged cells when compared to young cells undergoing stimulation with LPS, flagellin, and 
peptidoglycan, a finding consistent with our hypothesis that aging enhances the innate 
immune response of vascular smooth muscle via TLR-dependent pathways.  MCP-1 
production, however, was decreased in the aged cells when compared to the young cells 
across all three TLR agonists, a finding contrary to this hypothesis.   
 
Figure 3: Production of IL-6 by vascular smooth muscle cells derived from CBA mice 
following stimulation with the TLR-4 agonist LPS 
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Figure 4: Production of IL-6 by vascular smooth muscle cells derived from CBA mice 
following stimulation with the TLR-2 agonist peptidoglycan 
 
Figure 5: Production of IL-6 by vascular smooth muscle cells derived from CBA mice 
following stimulation with the TLR-3 agonist poly I:C 
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Figure 6: Production of IL-6 by vascular smooth muscle cells derived from CBA mice 
following stimulation with the TLR-9 agonist CpG 
 
Figure 7: Production of IL-6 by vascular smooth muscle cells derived from CBA mice 
following stimulation with the TLR-5 agonist flagellin 
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Figure 8: Production of IL-6 by vascular smooth muscle cells derived from aged CBA 
mice following stimulation with various TLR agonists 
 
 
Figure 9: Production of IL-6 by vascular smooth muscle cells derived from young CBA 




Figure 10: Production of MCP-1 by vascular smooth muscle cells derived from CBA 
mice following stimulation with the TLR-4 agonist LPS 
 
Figure 11: Production of MCP-1 by vascular smooth muscle cells derived from CBA 
mice following stimulation with the TLR-2 agonist peptidoglycan 
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Figure 12: Production of MCP-1 by vascular smooth muscle cells derived from CBA 
mice following stimulation with the TLR-3 agonist Poly I:C 
 
Figure 13: Production of MCP-1 by vascular smooth muscle cells derived from CBA 
mice following stimulation with the TLR-9 agonist CpG 
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Figure 14: Production of MCP-1 by vascular smooth muscle cells derived from CBA 
mice following stimulation with the TLR-5 agonist flagellin 
 
Figure 15: Production of MCP-1 by vascular smooth muscle cells derived from aged 
CBA mice following stimulation with various TLR agonists 
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Figure 16: Production of MCP-1 by vascular smooth muscle cells derived from young 
CBA mice following stimulation with various TLR agonists 
 
Tissue culture experiment:  IL-6 production may be elevated in aged vessels 
stimulated with LPS compared to baseline and young stimulated and unstimulated 
vessels, MCP-1 production differences are also seen 
 
 Based on the differences seen in the vascular smooth muscle cell culture model 
between aged and young cells, further study was done using a tissue culture model in an 
attempt to replicate the data seen in the cell culture in a more physiologic system.  Given 
the success of LPS stimulation when compared with stimulation by other TLR agonists 
during the initial cell culture experiment and the large body of evidence suggesting a role 
for TLR-4 signaling in the pathogenesis of atherosclerosis, a decision was made to use 
LPS stimulation for this next phase of the experiment.  During the initial experiment, 3 
aged and 3 young vessels were cultured from mice with a CBA background with 
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supernatants being taken only once from each vessel (i.e. 1 aged and 1 young vessel were 
stimulated for 6 hours, 1 each for 24 hours, and 1 each for 48 hours).  The results of this 
experiment are shown in figures 17 and 18 below. 
 During this initial tissue culture experiment, IL-6 production in aged vessels was 
notably elevated when compared to baseline production at all time points, while IL-6 
production in young vessels was elevated above baseline only at 48 hours.  In addition, 
the production of IL-6 in aged vessels was notably elevated above that of young vessels 
at all time points, supporting our hypothesis that aging enhances the TLR-4 dependent 
innate immune response of vascular smooth muscle cells. 
  The MCP-1 data from this experiment did not clearly favor the immune response 
of aged or young vessels.  At 6 and 24 hours, MCP-1 production in aged vessels was 
slightly higher than in young vessels, although at 6 hours production was near baseline in 
both stimulated vessels.  At 48 hours, young vessels produced significantly more MCP-1 
than did the aged vessels.  Although the aged vessels produced more MCP-1 than did 
their your counterparts at two of three time points, the data was not as clear cut as that 
seen with IL-6, and it was difficult to draw any meaningful conclusions from this assay, 




Figure 17: Production of IL-6 by tissue culture of stimulated and unstimulated young and 
aged vessels of CBA mice 
 
 
Figure 18: Production of MCP-1 by tissue culture of stimulated and unstimulated young 
and aged vessels of CBA mice 
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 In order to gain a better understanding of the differences seen in these tissue 
cultures, the experiment was run again, this time using 3 young and 6 aged mice per 
group, again from a CBA background.  For this second iteration of the experiment, data 
points were taken from each mouse at 12 hours, 24 hours, 48 hours, and 72 hours 
respectively, in order to maximize the amount of data available at each time point to 
increase the statistical power of the study.  Data is shown below in figures 19-22.  As was 
seen in the first tissue culture experiment, IL-6 production was increased in aged mice at 
early time points (12 and 24 hours).  Significant heterogeneity of results was seen at 48 
and 72 hours, and while IL-6 production was greater in the young vessels than in the aged 
vessels at these time points, these differences were not statistically significant.   
In an attempt to provide further mechanistic data regarding the production of IL-6 
by the tissue culture in response to TLR-4 stimulation with LPS, the aged mice that had 
undergone T cell ablations were separated from those that had not (figure 20).  If the 
production of IL-6 was mediated by resident T cells, we would expect to see a significant 
reduction of IL-6 production in the T cell ablated mice when compared to the normal 
aged mice.  A notable difference was seen at 48 hours between the ablated and normal 
mice (with less IL-6 production in the ablated mice) although this difference did not rise 
to the level of statistical significance.  At other time points, IL-6 production was 
comparable in both sub-groups.  Furthermore, IL-6 production in the ablated mice was 
significantly elevated above baseline levels of production.  This suggests that the 
production of IL-6 in the tissue culture model is not mediated by T cells resident in the 
vasculature.  
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It is difficult to draw conclusions about the effect of aging on the TLR-4 
dependent production of IL-6 in vascular smooth muscle based on this data, given the 
significant heterogeneity of the results and the inconsistent results, particularly at late 
time points.  It may be that cell death begins to occur at the later time points, leading to 
the heterogeneity of inconsistency of the results.  From these preliminary results, a trend 
has emerged which suggests the possibility that aged cells produce more IL-6 than do 
young cells in response to TLR-4 stimulation, particularly as measured at early time 
points (6-24 hours), although this is far from certain. 
Similarly, it is difficult to draw conclusions from the production of MCP-1 seen in 
this second experiment.  At early time points (12 and 24 hours), the aged and young cells 
produced very similar amounts of MCP-1.  At the late time points (48 and 72 hours), the 
young cells produced more MCP-1 than did the aged cells, although again, there was 
significant heterogeneity of the results, which did not rise to the level of statistical 
significance.  As with IL-6, there was no significant difference between normal aged 
mice and mice s/p T cell ablation (figure 22), suggesting that the production of MCP-1 in 
response to stimulation with the TLR-4 agonist LPS is not mediated by T-cells resident in 
the vessel wall.  Given the variability seen between the experiments and the heterogeneity 
of the results, it is difficult to draw conclusions regarding the effect of aging on 




Figure 19: Production of IL-6 by tissue culture of stimulated and unstimulated young and 
aged vessels of CBA mice 
 
Time Young-Stimulated Aged-Stimulated Young-Unstimulated Aged-Unstimulated 
 Mean SEM Mean SEM Mean SEM Mean SEM 
12H 51,322 14,954 91,129 33,433 29,275 7,321 21,501 10,537 
24H 70,761 28,648 183,490 56,443 48,092 7,266 28,510 7,638 
48H 218,277 83,911 196,162 72,562 69,091 29,499 44,311 11,091 
72H 330,165 157,349 221,421 80,432 124,629 57,568 27,509 11,987 
 
Table 1: Mean values and Standard Error of Mean for Graph in Figure 19 
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Figure 20: Production of IL-6 by tissue culture of stimulated and unstimulated aged 
vessels of CBA mice – normal mice vs. T cell ablated mice 
 
Time Ablated-Stimulated Normal-Stimulated Ablated-Unstimulated Normal-Unstimulated 
 Mean SEM Mean SEM Mean SEM Mean SEM 
12H 82,592 66,232 95,397 45,224 11,514 1,857 26,495 15,877 
24H 164,020 83,251 193,225 81,944 32,019 6,700 26,756 11,632 
48H 136,019 119,837 226,234 99,325 18,216 872 57,358 11,713 
72H 236,668 221,887 213,798 88,936 11,218 5,545 35,655 16,964 
 




Figure 21: Production of MCP-1 by tissue culture of stimulated and unstimulated young 
and aged vessels of CBA mice 
 
Time Young-Stimulated Aged-Stimulated Young-Unstimulated Aged-Unstimulated 
 Mean SEM Mean SEM Mean SEM Mean SEM 
12H 24,183 2,937 25,785 8,189 6,282 2,150 6,346 1,371 
24H 27,508 9,709 24,953 6,758 13,261 4,088 7,384 2,036 
48H 39,698 16,812 26,865 7,678 13,354 8,048 5,584 990 
72H 50,703 21,977 42,398 13,797 17,933 2,400 8,383 2,029 
 




Figure 22: Production of MCP-1 by tissue culture of stimulated and unstimulated aged 
vessels of CBA mice – normal mice vs. T cell ablated mice 
 
Time Ablated-Stimulated Normal-Stimulated Ablated-Unstimulated Normal-Unstimulated 
 Mean SEM Mean SEM Mean SEM Mean SEM 
12H 24,034 19,153 26,661 10,283 3,866 33 7,586 1,779 
24H 22,388 14,830 26,236 8,711 5,232 3,003 8,460 2,775 
48H 29,473 17,966 25,562 9,586 5,214 1,615 5,770 1,408 
72H 50,521 32,199 38,336 16,930 4,927 654 10,110 2,690 
 




 Given the significant heterogeneity and inconsistency of the results of these 
experiments and the limited number of samples included in the analysis, it is difficult to 
draw any meaningful conclusions about the effect of aging on the TLR mediated immune 
response of vascular smooth muscle cells from this study.   
 
Presence of various Toll-like receptors: 
 
 Our experiments with the vascular smooth muscle cell culture supports previous 
work done on the subject, in that stimulation with TLR-2 and TLR-4 agonists generated 
an immune response in the form of significant elevations in the production of MCP-1 and 
IL-6 [40].  Stimulation with the TLR-3 and -9 agonists Poly I:C and CpG did not yield a 
significant response.   Interestingly, stimulation with flagellin, a TLR-5 agonist, did yield 
a response, with elevations in the production of MCP-1 and IL-6 comparable to that seen 
with peptidoglycan stimulation.  In fact, among the various TLR agonists used in the cell 
culture experiment, flagellin stimulation produced the most clearly divergent curves 
between aged and young cells with respect to IL-6 production.  In contrast with TLR-2 
and -4, a literature search revealed no documentation of TLR-5 expression in vascular 
smooth muscle cells and no evidence of cross-reactivity of flagellin with the TLR-2 or -4 
receptor.   
Early studies of toll-like receptor signaling demonstrated activation of TLR-2 
with LPS, although later studies demonstrated that purification of the commercial LPS 
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preparation negated this effect, suggesting that this cross-reactivity was due to a 
biological contaminant [60].  It is possible that the effect on VSMCs seen in our 
experiment is due to a similar contamination, although it is also possible that VSMCs do 
in fact express TLR-5, and that stimulation of the TLR-5 receptor by flagellin-bearing 
pathogens may play a role in the induction of an immune response in these cells, although 
further study is necessary to elucidate what, if any, role TLR-5 stimulation plays in this 
process.  Experiments with TLR4 knockout VSCMs would evaluate whether 
contamination with TLR4 agonists is contributing to the activation of VSMCs with the 
flagellin mixture. 
 
Limitations of the Cell and Tissue Culture Models: 
A significant limitation of the cell culture model is that it is unclear to what 
degree aged and young cells retain their phenotypic differences through the process of 
proliferation, growth, division and passage in an in vitro setting.  It is possible that in the 
artificial environment of a culture flask, this process results in a reversion of the aged 
cells to a younger phenotype.  This limitation of the cell culture model was part of the 
impetus for the development of the tissue culture model. 
Another significant limitation of the cell culture model and the first trials of the 
tissue culture model is in the limited number of samples analyzed in each experiment.  
Using only one time point from each cell and tissue culture makes it difficult to 
determine whether the differences seen between the aged and young cells represent true 
significant differences or merely statistical anomalies.  In both cell and tissue culture 
models, decreased levels of cytokine production were seen at later time points when 
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compared with earlier time points in some experiments (IL-6, figure 3, MCP-1, figure 
18).  Because these time points do not reflect analysis of the same samples, it cannot be 
determined whether this decrease was due to cytokine instability and degradation over 
time, or simply due to an anomaly in one of the samples that was not present in the 
others, such as the presence of differing levels of endothelial cells or fibroblasts in 
addition to the smooth muscle cells, which affected the production of these cytokines.  
Multiple time points were examined for each sample in the second tissue culture 
experiment in order to correct for this limitation.    
One significant limitation of this study that may have led to the generation of 
inaccurate results is that in the tissue culture model, results were not adjusted for vessel 
weight.  As a result, the seemingly elevated production of IL-6 in the aged vessels may 
simply have been due to the presence of more tissue in these cultures.  More recent 




 In summary, in both the cell and tissue culture models, IL-6 production was 
elevated in aged cells when compared to young cells following stimulation of TLR-4 
with LPS.  However, this effect was the least pronounced in the third experiment, in 
which the most data was generated.  In this third experiment, a clear increase was found 
only at one of the four time points seen (24 hours).  Furthermore, more recent studies, 
completed after the student finished working in the lab, have shown the opposite effect, 
with IL-6 production decreased in aged cells when compared to young cells (data not 
 48
shown).  The heterogeneity of our results, combined with the recent contradictory results, 
make it difficult to draw any meaningful conclusions about the role that aging might play 
in the magnitude of the TLR-4 dependent immune response of VSMCs, and further study 
is ongoing to determine what, if any, differences exist between aged and young vessels in 
regard to this signaling pathway.   
 
MCP-1 Production:  
 
 Like IL-6, the data regarding MCP-1 production is inconclusive.  In the majority 
of time points in the majority of the experiments, the young cells and vessels produced 
more MCP-1 than did the aged cells in response to TLR-4 stimulation, although these 
differences did not rise to the level of statistical significance, and there was considerable 
variability and heterogeneity of the results.  Our hypothesis, based on the studies 
discussed earlier, was that both MCP-1 and IL-6 would be produced in higher 
concentrations in the aged cells than in the young cells.  As discussed, it has been shown 
that aging accelerates the process of atherosclerosis, that TLR-4 dependent signaling is 
involved in the process of atherosclerosis, that VSMCs produce the pro-inflammatory 
cytokines MCP-1 and IL-6 in response to TLR-4 stimulation, and that at least part of the 
accelerations in atherogenesis seen in aged vessels is due to differences in the function of 
VSMCs.  For those reasons, it seemed likely that TLR stimulation would lead to 
increased production of IL-6 and MCP-1 in aged vessels and vascular smooth muscle 
cells when compared to young vessels and cells.  Our data on MCP-1 production does not 
support this hypothesis.  One possible explanation for the different levels of production of 
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MCP-1 and IL-6 in response to TLR stimulation is that promoters of the MCP-1 and IL-6 
genes may be differentially occupied (e.g. by repressors) in various subsets and/or ages of 
cells.  However, our data is far from conclusive in regards to this differential production, 
and further studies are ongoing to determine what, if any, role aging may play in the 





In conclusion, our study generated preliminary data suggesting that aged vascular 
smooth muscle produces more of the pro-inflammatory cytokine IL-6 and less of the pro-
inflammatory chemokine MCP-1 than does young vascular smooth muscle.  However, 
the significant heterogeneity and inconsistency of these results makes it difficult to draw 
meaningful conclusions from our data, and further studies are ongoing to further 




 Further study is warranted to determine what differences exist between aged and 
young cells in terms of the production of pro-inflammatory cytokines in response to TLR 
stimulation.  Further tissue culture experiments with LPS stimulation will be performed, 
in which samples are normalized for weight.  This normalization and repetition should 
increase the statistical power of this study, and allow for more meaningful conclusions to 
be made. 
 In addition, further study is warranted on the role that TLR-5 stimulation with 
flagellin may play in the immune response of VSMCs, as well as the role that aging 
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